Recent Finacing
Recent Raise
Solu Therapeutics develops CyTAC/CyTaC and TicTAC therapeutics to eliminate disease-driving cells, advancing STX-0712 (CCR2-targeting CyTAC) in a Phase 1 trial for CMML.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Solu Therapeutics.
